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Abstract
Background

Previous studies evaluating the risk of cardiovascular diseases (CVD) in

prostate cancer patients receiving androgen deprivation treatment (ADT) often did not
distinguish different modalities of ADT.
Methods

We conducted a large, retrospective cohort study using the linked Surveillance,

Epidemiology and End Results - Medicare database, including patients with primary
localized prostate cancer diagnosed in 2007-2013 and followed through the end of 2014.
Time dependent multivariable Cox proportional hazards models with death as the competing
risk were used to evaluate the association between ADT (overall, and two subtypes:
gonadotropin-releasing hormone [GnRH] agonists and oral antiandrogens) and incidence of
CVD.
Results

Among 20,239 prostate cancer patients, 32% received ADT. Receipt of ADT

was associated with a 28% increase in the risk of CVD (hazard ratio [HR] = 1.28, 95%
confidence interval [CI]: 1.14-1.67). The HRs for GnRH agonists and oral antiandrogens
were 1.22 (95% CI: 1.15-1.30) and 1.11 (95% CI: 1.04-1.20), respectively.
Conclusions

In patients with primary, localized prostate cancer, ADT is associated with a

significantly increased risk for CVD, and the magnitude of association appears higher for
GnRH agonists than for oral antiandrogens.

2

TABLE OF CONTENTS

INTRODUCTION ..................................................................................................................... 4
METHODS ................................................................................................................................ 5
DATA SOURCE AND STUDY COHORT ......................................................................................... 5
ASCERTAINMENT OF ADT ......................................................................................................... 6
STUDY OUTCOMES ................................................................................................................... 6
OTHER VARIABLES OF INTEREST .............................................................................................. 7
STATISTICAL ANALYSIS ........................................................................................................... 8

RESULTS .................................................................................................................................. 9
DISCUSSION .......................................................................................................................... 10
REFERENCES ........................................................................................................................ 14
LIST OF TABLES AND FIGURES ....................................................................................... 17
LIST OF APPENDIXS ............................................................................................................ 27

3

Introduction
Prostate cancer is the most common type of cancer and the second leading cause of
cancer mortality among men in the United States (US).1 An estimated 164,690 men will be
diagnosed with prostate cancer in 2018 in the US2 and will face a decision with respect to
therapy. Androgen deprivation therapy (ADT) is the mainstay treatment for prostate cancer 45% of prostate cancer patients are expected to receive some form of ADT in the course of
their disease.3 Although ADT has been shown to reduce cancer-specific mortality, it is also
associated with several side effects including reduced libido, erectile dysfunction,
gynaecomastasia, depression, metabolic alterations, dementia and kidney failure.4-9 In
addition, several studies have suggested that ADT, especially gonadotropin-releasing
hormone (GnRH) agonists, may be associated with an increased risk of cardiovascular
diseases (CVD).10-14 Consequently, the US Food and Drug Administration issued a safety
warning regarding the increased CVD risk of GnRH agonists in 2010.15
Previous studies on ADT and risk of CVD mainly investigated GnRH agonists. Oral
antiandrogens, which has gained popularity in recent years.16,17 Few studies are available on
different modalities of ADT and risk of CVD. A recent French study suggests that CVD risk
may differ across ADT modalities, but the difference may not be meaningful. However, this
study only followed patients up to 4 years18. In addition, studies which combined different
modalities of ADT have contradictory findings regarding the association between ADT and
the risk of CVD in prostate cancer patients.10,11,19,20 Punnen et al. observed no association
between ADT and CVD specific mortality with patients matched by propensity scores,19
4

while Ziehr et al. reported that the association only existed in patients with preexisting
CVD20. A Kaiser based study indicated a moderate association.10,11 However, insufficient
data were available on different types of ADT.
The purpose of this study is to fill the knowledge gaps identified above by assessing the
potential association between the receipt of ADT (overall, as well as three subtypes: GnRH
agonists, oral antiandrogens, and orchiectomy) and CVD risk in a large cohort of prostate
cancer patients in the US.

Method
Data Source and Study Cohort
We used the Surveillance, Epidemiology and End Results (SEER) - Medicare database,
which links patient-level information on incident cancer diagnoses reported to the SEER
registries with Medicare claims for inpatient, outpatient, and physician services21. The SEER
registries are population-based and account for approximately 28% of the US population22.
The Yale human investigation committee determined this study did not directly involve
human subjects.
We assembled a retrospective cohort of 32,234 patients newly diagnosed with first
primary, localized prostate cancer (clinical stage T1 or T2) during 2007-2013 with the
following eligibility criteria: 1) aged 66 to 99 years at diagnosis, 2) had known month of
diagnosis, 3) were not reported from autopsy or death certificate only, and 4) had continuous
Medicare fee-for-service coverage (Parts A and B) and was not enrolled in health
5

maintenance organizations from 12 months before diagnosis to the end of follow-up (i.e., the
date a patient developed the first CVD event, the date a patient died, or December 31, 2014,
whichever was earlier), and 5) continuously enrolled in Medicare Part D from diagnosis to
the end of follow-up. To ensure all CVD events were newly developed after prostate cancer
diagnosis, we further excluded patients who had Medicare claims indicative of CVD in the 12
months before (n = 9889) or during (n = 194) the month of their prostate cancer diagnosis.
Additionally, we excluded patients who received ADT before their prostate cancer diagnosis
(n = 84), and patients who developed CVD between the diagnosis of prostate cancer and
when they received ADT for the first time (n = 1034). The final study cohort consisted of
20,239 patients (Figure 1).

Ascertainment of ADT
Using Medicare claims, we ascertained there different types of ADT: 1) GnRH
analogists (Healthcare Common Procedure Coding System codes J9217, J9218, J9219,
J1950, J9202, and relevant Medicare Part D drug national drug codes (NDCs) ; see Appendix
Table 1); 2) orchiectomy (Common Procedure Terminology codes 54512, 54521, 54522,
54530, 54535, 54690, and ICD-9 Procedure codes 62.3, 62.4, 62.41, and 62.42; see Appendix
Table 2); and 3) oral antiandrogens ( Medicare Part D drug NDC codes; see Appendix Table
1-2). The use of ADT overall and the three different types of ADT were evaluated
dichotomously (ever vs. never).
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Study Outcomes
We identified CVD events after diagnosis based on the International Classification of
Diseases, 9th edition [ICD-9] codes from Medicare claims (see Appendix 3). We required
diagnosis codes must appear on one inpatient claim or at least two different claims that are
more than 30 days apart. If a patient had multiple CVD events on the same date, the patient
was assigned to a specific outcome group according to the sequence below: 1) acute
myocardial infarction (AMI); 2) cardiac arrest; 3) stroke; 4) heart failure; 5) hypertensive
heart disease with heart failure; 6) cardiomyopathy; 7) valvulopathy; 8) angina pectoris; and
9) conduction disorder. CVD events were first evaluated as a single entity and then classified
into three separate categories: 1) cardiac ischemia (including AMI, cardiac arrest and angina
pectoris); 2) stroke; and 3) other CVD (including heart failure, cardiomyopathy, conduction
disorder, hypertensive heart disease and valvulopathy).

Other Variables of Interest
To assess comorbidity, all inpatient, outpatient and carrier claims within 12 months
before the date of prostate cancer diagnosis were identified to calculate a modified Elixhauser
comorbidity score (0, 1, >1)23,24. In addition, we abstracted information on a number of
sociodemographic and clinical characteristics, including age at prostate cancer diagnosis (6569, 70-74, 75-79, ≥80 years), race (white, non-white), marital status (married/unmarried),
census division (northeast, midwest, south, west), residential area (urban/rural), percentage of
residents living in poverty at the census tract level (<10%, ≥10%), clinical stage at diagnosis
7

(T1/T2), Gleason score (<7, 7, >7), level of prostate specific antigen (0.1-9.9, 10.0-20.0,
≥20.1), influenza vaccination in the last 12 months (yes/no, as a proxy measure for healthcare
utilization), and radiotherapy for prostate cancer (yes/no).

Statistical Analysis
Frequency distributions of demographic and socioeconomic characteristics were
compared between prostate cancer patients who received ADT and those who did not receive
ADT, using Pearson’s Chi-square tests. Death prior to the first CVD event was considered a
competing risk event. All patients were followed till the development of their first CVD
event, death, or December 31, 2014, whichever was earlier. The outcomes of interest were
occurrences of the first CVD event. To account for patients transferring from one group to
another group, Simon-Makuch method was used for a graphical representation of the
probability of cardiovascular diseases according to the receipt of ADT, which was considered
as a time-dependent variable.25 Competing risk Cox proportional hazards regression models
using the Find and Gray method were used to provide estimates of the crude and adjusted
hazard ratios (HRs) and corresponding 95% confidence intervals (CI) for the occurrence of
CVD events.26 To account for immortal bias27, for a given patient, person-time before the
receipt of the first ADT was considered unexposed to ADT and exposed thereafter. All
variables described in the previous section were included in the models. In addition to
analyzing ADT as one group, we also analyzed different types of ADT separately by
including the three types of ADT in the same model simultaneously. As very few patients
8

received orchiectomy (either exclusively or in combination with GnRH agonists and/or oral
antiandrogens, n = 89), we chose to adjust for orchiectomy in the model but did not present
the results for orchiectomy separately. The proportional hazards assumption was tested by
plotting Schoenfeld residuals.
All tests were two-sided with p<0.05 indicating statistical significance. SAS version 9.4
(SAS Inc. Cary, NC) was used to conduct the analyses.

Results
Baseline Characteristics
A total of 20,239 men with primary localized prostate cancer were included in the cohort.
Patients who received ADT were more likely to be older, black, unmarried, poorer, in T1
stage and have received radiotherapy for prostate cancer (Table 1).
Of these 20,239 patients, 6490 (32.1%) received ADT. Specifically, 3121 (15.4%), 588
(2.9%), and 41 (0.2%) exclusively received GnRH agonists, oral antiandrogen, or
orchiectomy, respectively; but a large number of prostate cancer patients (n = 2740, 13.5%)
received combinations of two or three different types of ADT (Figure 2).
After a mean follow-up of 4.1 (range:1-8) years, 26.9% (n=5463) patients developed
CVD. As shown in Figure 3, 2995 (14.8%), 611(3.0%), and 1857 (9.2%) patients
experienced cardiac ischemia, stroke and other CVD events, respectively.
As shown in Figure 4, patients received ADT were more likely to develop CVD
(p=0.003). In the multivariate models, prostate cancer patients treated with ADT had a
9

significantly higher risk of developing CVD events compared with patients who did not
receive ADT (HR = 1.28, 95% CI: 1.22 - 1.36; P < .0001) (Table 2). When further evaluated
three groups of CVD events, receipt of ADT increased risk of cardiac ischemia, stroke, and
other CVDs by 20% (95% CI: 1.10 - 1.32), 38% (95% CI: 1.14 - 1.67) and 39% (95% CI:
1.25 - 1.54), respectively (Table 3). Among the nine specific types of CVD, significant
associations were observed with angina pectoris, heart failure, hypertensive heart disease, and
valvulopathy (Table 3).
Based on a multivariable model that included GnRH agonists, oral antiandrogens,
orchiectomy as binary variables simultaneously, we found that both GnRH agonists and oral
antiandrogens were associated with a statistically significant, increased risk for CVD (Figure
5), while orchiectomy did not appear to influence CVD risk. The magnitude of association
with CVD as a single entity was higher for GnRH agonists (HR = 1.22; 95% CI: 1.15 - 1.30)
than for oral antihydrogens (HR = 1.11, 95% CI: 1.01 - 1.20). In addition, analyses by the
three groups of CVD suggested that receipt of GnRH agonists was significantly associated
with increased risks of cardiac ischemia and other CVDs, but not stroke, while taking oral
antiandrogens was associated with an increased risk of stroke, but not cardiac ischemia or
other CVD (details not shown).

Discussion
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In this large population-based cohort of older prostate cancer patients, we found that
ADT is significantly associated with an increased risk of CVD, and the magnitude of
association appears higher for GnRH agonists than for oral antiandrogens.
Most previous studies on ADT and risk of CVD mainly focused on GnRH agonists
solely ADT.5,11,12,14,28-33 We were able to identify the use of GnRH agonists, oral
antiandrogens, and orchiectomy from SEER-Medicare claims and accounted for a
comprehensive set of sociodemographic and clinical characteristics of the patients as
potential confounders. A previous study using SEER-Medicare database compared the 10year rates of CVD between ADT users and non-ADT users, however, they did not include
oral antiandrogens as ADT12.
Utilizing the SEER-Medicare database, we found significantly increased risks of most
CVD events among prostate cancer patients who received ADT. This finding is consistent
with several other studies that were based on large databases6,10,12-14,29. A recent prospective
cohort study from Kaiser Permanente only found an increased risk of heart failure in men
without preexisting CVD11. However, the Kaiser study included patients at all ages, thus 38%
of patients in the Kaiser cohort were under the age of 65 years, while our cohort consists of
Medicare beneficiaries who were at least 66 years in age.
Our study evaluated the impact of ADT on CVD risk across modalities, with a focus on
oral antiandrogens. Oral antiandrogens have been used more often in recent years but have
not been systematically studied in terms of their impact on CVD risk16. Although oral
antiandrogens are often used with other therapies, a recent randomized controlled trial
11

showed that there was no difference in all-cause mortality and prostate cancer related
mortality between antiandrogen monotherapy and GnRH agonists17. In a French study,
compared with GnRH agonists, combined androgen blockade was associated with an
increased risk (HR= 1.6, 95% CI:1.3 - 2.0) and antiandrogen with a decreased risk (HR = 0.6,
95% CI: 0.4 - 0.9) of ischaemic events18. We found that patients who received GnRH
agonists had a higher risk of most CVD outcomes including cardiac ischemia, heart failure,
cardiomyopathy and hypertensive heart disease, compared with patients who received oral
antiandrogens. These are similar to the findings by Keating et al10. However, we also found
that the use of oral antiandrogens was associated with a significantly increased risk of stroke,
while GnRH agonists did not appear to influence stroke risk. Given the paucity of studies on
oral antiandrogens and the lack of confirmation, our findings should be interpreted with
caution, but they do underscore the importance of studying different subtypes of ADT. It may
not be reasonable to treat ADT as a single entity when evaluating its impact on CVD risk.
Our study has several strengths. First, the SEER-Medicare database enabled us to have a
large sample size and a long follow-up of the patients, which is crucial for the ascertainment
of CVD outcomes. Second, we take account a complete subtypes of ADT and include the
information of oral antiandrogens, which have been used more often recently. Additionally,
the time-dependent competing-risk Cox proportional hazards regression models allowed us to
address immortal bias in the study.
Some limitations of our study should also be noted. With a retrospective cohort design,
patients were not randomly assigned to treatment with ADT, and comparison of baseline
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characteristics showed that sicker and older patients were more likely to receive ADT.
Although we adjusted for a number of covariates in the model, residual confounding might
still exist. Second, our study cohort only included older patients (age ≥ 66 years) who had
continuous Medicare coverage and no pre-existing CVD, which likely limits the
generalizability of our findings. In addition, multiple comparison problem may exist in this
study as we have three major types of CVD outcomes and two subtypes of ADT. However,
the p-values would be still significant after Bonferroni adjustment as almost all p-values for
the three major types of CVD are smaller than 0.001. Finally, we were unable to analyze the
association between orchiectomy and CVD risk due to the very small number of patients who
underwent the surgical procedure.
In conclusion, receipt of ADT is associated with an increased risk of CVD events in
older men with localized prostate cancer. Compared with oral antiandrogens, GnRH agonists
appears to confer a higher CVD risk. It is important for prostate cancer patients and their
physicians to take the association between ADT and CVD risk into account when making
treatment decisions.
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Figure 1. Construction of Study Cohort Using the Linked SEER-Medicare Database. *
CVD indicates cardiovascular diseases; PCa, prostate cancer; ADT, androgen deprivation
therapy.
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Table 1. Sociodemographic and Clinical Characteristics of Prostate Cancer Patients at
Baseline by Receipt of Androgen Deprivation Therapy
Overall

Androgen Deprivation Therapy
Never
EVER
13749
6490

Total
20239
Age (years)
<70
6992 (34.6)
5440 (39.6)
70 – 74
7336 (36.3)
5174 (37.6)
75 – 79
3805 (18.8)
2231 (16.2)
≥80
2106 (10.4)
904 (6.6)
Race
White
16480 (81.4)
11458 (83.3)
Non-white
3759 (18.6)
2291 (16.7)
Marital status
Married
13320(65.8)
9312 (67.7)
Unmarried
3977 (19.7)
2548 (18.5)
Census Region
Northeast
3603 (17.8)
2277 (16.6)
Midwest
2672 (13.2)
1719 (12.5)
South
4898 (24.2)
3406 (24.8)
West
9066 (44.8)
6347 (46.2)
Residential Area
Urban
16189 (80.0)
11651 (81.2)
Rural
4046 (20.0)
2584 (18.8)
% of Residents Living Under Census Tract
<10%
10659(52.7)
7461 (54.3)
≥10%
9348 (46.2)
6125 (44.6)
Clinical stage at diagnosis
T1
12684 (62.7)
9097 (66.2)
T2
7555 (37.3)
4652 (33.8)
Gleason score
<7
7913 (39.1)
6678 (48.6)
7
7971 (39.4)
5308 (38.6)
>7
3101 (15.3)
905 (6.6)
Prostate Specific Antigen
0.1-9.9
15890 (78.5)
11782 (85.7)
10.0-20.0
2869 (14.2)
1528 (11.1)
≥20.1
1480 (7.3)
439 (3.2)
Elixhauser Score
0
13418 (63.8)
8968 (65.2)

P-value*

1552 (23.9)
2162 (33.3)
1574 (24.3)
1202 (18.5)

<0.0001

5022 (77.4)
1468 (22.6)

<0.0001

4008 (61.8)
1429 (22.0)

<0.0001

1326 (20.4)
953 (14.7)
1492 (23.0)
2719 (41.9)

<0.0001

5028 (77.5)
1462 (22.5)

<0.0001

3198 (49.3)
3223 (49.7)

<0.0001

3587 (55.3)
2903 (44.7)

<0.0001

1235 (19.0)
2663 (41.0)
2196 (33.8)

<0.0001

4108 (63.3)
1341 (20.7)
1041 (16.2)

<0.0001

3937 (60.0)

<0.0001
18

1
5032 (24.9)
3312 (24.1)
1720 (26.5)
≥2
2343 (11.6)
1469 (10.7)
874 (13.5)
Influenza vaccine before diagnosis
Yes
9816 (48.5)
6641 (48.3)
3175 (48.9)
No
10423 (51.5)
7108 (51.7)
3315 (51.1)
Radiotherapy
Yes
10801 (53.4)
5971 (43.4)
4830 (74.4)
No
9438 (46.6)
7778 (56.6)
1660 (25.6)
*P-values were calculated using Pearson’s Chi-square test
Column totals may not equal to the total due to missing values.

0.41

<0.0001

19

GnRH &
Orhiectomy
0.06%
Orchiectomy Only
0.20%

Orchiectomy & Oral
AA
0.05%

GnRH & Oral AA &
Orchiectomy
0.12%

GnRH & Oral AA
13.30%

GnRH Only
15.42%
Non-ADT
67.93%
Oral AA Only
2.91%

Figure 2. Types of Androgen Deprivation Therapy Received by Prostate Cancer
Patients (n = 20,239)
* GnRH: gonadotropin-releasing hormone agonists; Oral AA: oral antiandrogens; ADT:
androgen deprivation treatment
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Cardiac
Ischaemia
15%

Stroke
3%

Other CVD
9%
No CVD
73%

Figure 3. Types of Cardiovascular Diseases Occurred in Prostate Cancer Patients (n =
20,239)
* CVD: cardiovascular diseases
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Figure 4. Probability of Cardiovascular Diseases by Androgen Deprivation Therapy
according to the Simon-Makuch method25
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Table 2. Sociodemographic and Clinical Characteristics, Androgen Deprivation
Therapy, and Risk of Cardiovascular Diseases in Prostate Cancer Patients*
Non-ADT
(N=13749)

ADT
(N=6490)

Hazard
Ratio
1.28

95% Confidence
P-value
Interval
1.22 - 1.36
<.0001

5440 (39.6)
5174 (37.6)
2231 (16.2)
904 (6.6)

1552 (23.9)
2162 (33.3)
1574 (24.3)
1202 (18.5)

1.00
1.16
1.36
1.63

1.10 - 1.23
1.27 - 1.45
1.51 - 1.76

<.0001
<.0001
<.0001

11458 (83.3)
2291 (16.7)

5022 (77.4)
1468 (22.6)

1.00
1.09

1.03 - 1.16

0.003

9312 (67.7)
2548 (18.5)
1889 (13.7)

4008 (61.8)
1429 (22.0)
1053 (16.2)

1.00
1.06
0.99

1.00 - 1.12
0.93 - 1.06

0.047
0.874

2277 (16.6)
1719 (12.5)
3406 (24.8)
6347 (46.2)

1326 (20.4)
953 (14.7)
1492 (23.0)
2719 (41.9)

1.00
1.02
1.02
0.89

0.94 - 1.11
0.95 - 1.09
0.83 - 0.94

0.652
0.647
<.0001

Urban
11651 (81.2)
5028 (77.5)
Rural
2584 (18.8)
1462 (22.5)
% of Residents Living Under Census Tract
<10%
7461 (54.3)
3198 (49.3)
≥10%
6125 (44.6)
3223 (49.7)
Gleason score
<7
6678 (48.6)
1235 (19.0)
7
5308 (38.6)
2663 (41.0)
>7
905 (6.6)
2196 (33.8)
Prostate-specific antigen
0.1-9.9
11782 (85.7)
4108 (63.3)
10.0-20.0
1528 (11.1)
1341 (20.7)
≥20.1+
439 (3.2)
1041 (16.2)
Elixhauser Score
0
8968 (65.2)
3937 (60.0)

1.00
0.90

0.85 - 0.96

0.001

1.00
0.97

0.92 - 1.02

0.187

1.00
1.01
0.94

0.96 - 1.07
0.87 - 1.01

0.616
0.097

1.00
0.95
0.80

0.89 - 1.01
0.73 - 0.88

0.100
<.0001

ADT
Age (years)
<70
70 – 74
75 – 79
≥80
Race
White
Non-white
Marital status
Married
Unmarried
Missing
Census Region
Northeast
Midwest
South
West

Residential Area

1.00
23

1
2
Radiotherapy
No
Yes

3312 (24.1)
1469 (10.7)

1720 (26.5)
874 (13.5)

1.28
1.58

1.22 - 1.35
1.48 - 1.69

<.0001
<.0001

7778 (56.6)
5971 (43.4)

1660 (25.6)
4830 (74.4)

1.00
0.94

0.89 - 0.98

0.008

Adjusted hazard ratios and 95% confidence intervals were derived from a multivariate,
competing-risk Cox proportional hazards regression model. All variables listed were
mutually adjust for each other.
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Table 3. Androgen Deprivation Therapy for Prostate Cancer and Risk of
Cardiovascular Diseases
% of patients
N

who have the
event

Adjusted HR
(95% CI)*

P-value

Overall

5463

26.9

1.28 (1.22- 1.36)

<0.001

Cardiac Ischemia

2995

14.8

1.20 (1.10- 1.32)

<0.001

AMI

314

1.55

1.00 (0.76- 1.31)

1.00

Angina Pectoris

2646

13.07

1.22 (1.11- 1.35)

<0.001

35

0.17

1.88 (0.97- 3.63)

0.06

Stroke

611

3.02

1.38 (1.14- 1.67)

<0.001

Other heart diseases

1857

9.18

1.39 (1.25- 1.54)

<0.001

Heart failure

672

3.32

1.59 (1.34- 1.90)

<0.001

Cardiomyopathy

114

0.56

1.34 (0.89- 2.02)

0.16

Conduction disorder

18

0.09

1.06 (0.39- 2.91)

0.90

Hypertensive heart disease

36

0.18

3.04 (1.24- 7.49)

0.02

1017

5.02

1.22 (1.05- 1.41)

0.01

Cardiac arrest

Valvulopathy

*Adjusted hazard ratios (HR) and 95% confidence intervals (CI) were derived from a single
multivariable, competing-risk Cox proportional hazards regression model that adjusted for
the following covariates: age at prostate cancer diagnosis (65-69, 70-74, 75-79, ≥80 years),
race (white, non-white), marital status (married/unmarried), census division (northeast,
midwest, south, west), percentage of residents living in poverty at the census tract level
(<10%, ≥10%), Elixhauser score (0, 1, >1) and radiotherapy for prostate cancer (yes/no).
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Hazard Ratio (95% Confidence Interval)

Figure 5. Adjusted Hazard Ratios and 95% Confidence Intervals for Risk of CVD
Events in Prostate Cancer Patients Who Received GnRH Agonists or Oral
Antiandrogens*
1.7

1.5

Type
ADT
1.3

GnRH
Oral AA

1.1

0.9
Total CVD

CI

Stroke

Other CVD

*Competing-risk Cox proportional hazards model were adjusted for the following covariates:
age at prostate cancer diagnosis (65-69, 70-74, 75-79, ≥80 years), race (white, non-white),
marital status (married/unmarried), census division (northeast, midwest, south, west),
percentage of residents living in poverty at the census tract level (<10%, ≥10%), Elixhauser
score (0, 1, >1), radiotherapy for prostate cancer (yes/no) and orchiectomy(ever/never).
Abbreviations: AA: antiandrogens; ADT: androgen deprivation therapy; CVD:
cardiovascular disease; CI: cardiac ischemia; GnRH: gonadotropin-releasing hormone
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Appendix
Appendix 1. Codes Used to Identify Androgen Deprivation Therapy (Healthcare
Common Procedure Coding System [HCPCS], Current Procedural Terminology [CPT],
International Classification of Disease, Ninth Version [ICD-9])
Diagnosis or
procedure

GnRH
(Leuprolide injection)

HCPC
S
CPT

ICD-9
procedure

J9217
J9218
J9219
J1950

GnRH
(Goserelin injection)

Orchiectomy

J9202
54512
54520
54522
54530
54535
54690
62.3
62.4
62.41
62.42

Comments
Leuprolide acetate (for depot
suspension), 7. 5 mg
Leuprolide acetate, per 1 mg
Leuprolide acetate implant, 65 mg
Injection, leuprolide acetate (for
depot suspension), per 3. 75 mg
Goserelin acetate implant, per 3. 6
mg
Excise lesion testis
Removal of testis
Orchiectomy partial
Removal of testis
Extensive testis surgery
Laparoscopy orchiectomy
Unilateral orchiectomy
Bilateral Orchiectomy
Removal of both testes at same
operative episode
Removal of both testes at same
operative episode
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Appendix 2. Drugs Identified for Androgen Deprivation Therapy Using Medicare Part
D Claims
Type

GNN(Generic Name)
Buserelin
Buserelin
Goserelin
Leuprolide Acetate
Leuprolide Acetate
Leuprolide Acetate
Leuprolide Acetate
Leuprolide Acetate
Leuprolide
Leuprolide
Leuprolide
Leuprolide
Leuprolide
GnRH agonists
Leuprorelin
Leuprorelin
Leuprorelin
Leuprorelin
Leuprorelin
Naferelin
Naferelin
Triptorelin
Triptorelin
Triptorelin
Triptorelin
Degarelix
Abarelix
Histrelin
Flutamide
Bicalutamide
Nilutamide
Oral antiandrogens
Enzalutamide
Abiraterone

BRN (Brand Name)
Suprecur
Suprefact injectable
Zoladex
Lupron Depot
Prostap SR
Enantone
Lucrin Depot
Trenantone-Gyn
Lupron Depot
Prostap SR
Enantone
Lucrin Depot
Trenantone-Gyn
Lupron Depot
Prostap SR
Enantone
Lucrin Depot
Trenantone-Gyn
Synarel
Synarella
Decapeptyl SR
Gonapeptyl
Supprelin LA
Trelstar Depot
Firmagon
Plenaxis
Vantas
Eulexin
Casodex
Nilandron
Xtandi
Zytiga
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Appendix 3. International Classification of Disease, Ninth Version [ICD-9] Codes Used
to Identify Cardiovascular Diseases from Medicare Part B Claims
CVD diagnoses
ICD9
Comment
Acute Myocardial Infarction
410
Acute myocardial infarction
Cardiac Arrest
427.5
Cardiac arrest
430
Subarachnoid hemorrhage
431
Intracerebral hemorrhage
432
Other and unspecified intracranial hemorrhage
Stroke
434
Occlusion of cerebral arteries
436
Acute, but ill-defined, cerebrovascular disease
Heart Failure (HF)
428
Heart failure
Malignant hypertensive heart disease with
402.01
heart failure
Hypertensive Heart Disease
Benign hypertensive heart disease with heart
402.11
with HF
failure
Unspecified hypertensive heart disease with
402.91
heart failure
425.1
Hypertrophic cardiomyopathy
425.3
Endocardial fibroelastosis
425.4
Endocardial fibroelastosis
Cardiomyopathy
Cardiomyopathy in other diseases classified
425.8
elsewhere
425.9
Secondary cardiomyopathy, unspecified
Arrhythmias
427
Cardiac dysrhythmias
Valvulopathy
424
Other diseases of endocardium
Other acute and subacute forms of ischemic
411
heart disease
Angina Pectoris
413
Angina pectoris
414
Other forms of chronic ischemic heart disease
Conduction Disorder
426.9
Conduction disorder, unspecified
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